Literature DB >> 18555660

Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells.

Emilie E Vomhof-DeKrey1, Glenn Paul Dorsam2.   

Abstract

Vasoactive intestinal peptide receptor-1 (VPAC-1) is an anti-proliferative, G-protein coupled receptor that is highly expressed on naïve T cells, and has been reported to be downregulated upon T cell activation. The T cell signaling molecules involved in mediating low VPAC-1 levels have not been identified. Therefore, to gain a greater understanding into this regulation, this study investigated the signaling pathways that regulate (VPAC-1) in murine, primary CD4 T cells. To this end, murine, splenic CD4 T cells were pretreated separately with 10 different pharmacological inhibitors and incubated +/- anti-CD3 for 24h. Total RNA was isolated, and VPAC-1 mRNA levels were measured by qPCR. Our results support that JNK kinases, downstream from the protein kinase, Zap70, are involved in suppressive regulation of VPAC-1 steady-state mRNA levels after anti-CD3 treatment. In contrast, inhibitors against PKC, ERK, p38, Zap70 and Rac1 supported a stimulatory influence in VPAC-1 regulation in the absence of T cell signaling. By studying the signaling pathways that regulate VPAC-1 in T cells, we can gain greater insight into the role of this anti-inflammatory receptor in autoimmunity and infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18555660      PMCID: PMC2771589          DOI: 10.1016/j.bbi.2008.04.006

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  53 in total

Review 1.  Signal transduction by the TCR for antigen.

Authors:  L P Kane; J Lin; A Weiss
Journal:  Curr Opin Immunol       Date:  2000-06       Impact factor: 7.486

2.  Differential activation of phospholipase D by VPAC and PAC1 receptors.

Authors:  D A McCulloch; E M Lutz; M S Johnson; C J MacKenzie; R Mitchell
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

3.  Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells.

Authors:  M Lara-Marquez; M O'Dorisio; T O'Dorisio; M Shah; B Karacay
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

4.  Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals.

Authors:  M Xia; S P Sreedharan; E J Goetzl
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

Review 5.  Integration of T cell receptor-dependent signaling pathways by adapter proteins.

Authors:  J L Clements; N J Boerth; J R Lee; G A Koretzky
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

6.  Signaling through ZAP-70 is required for CXCL12-mediated T-cell transendothelial migration.

Authors:  Michel Ticchioni; Céline Charvet; Nelly Noraz; Laurence Lamy; Marcos Steinberg; Alain Bernard; Marcel Deckert
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

Review 7.  Signalling to transcription: store-operated Ca2+ entry and NFAT activation in lymphocytes.

Authors:  Yousang Gwack; Stefan Feske; Sonal Srikanth; Patrick G Hogan; Anjana Rao
Journal:  Cell Calcium       Date:  2007-06-18       Impact factor: 6.817

8.  Vasoactive intestinal polypeptide modulation of lymphocyte adenylate cyclase.

Authors:  M S O'Dorisio; N S Hermina; T M O'Dorisio; S P Balcerzak
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

9.  A protein kinase inhibitor, staurosporine, enhances the expression of phorbol dibutyrate binding sites in human polymorphonuclear leucocytes.

Authors:  C Combadière; E Pedruzzi; J Hakim; A Périanin
Journal:  Biochem J       Date:  1993-02-01       Impact factor: 3.857

10.  EGF-induced PIP2 hydrolysis releases and activates cofilin locally in carcinoma cells.

Authors:  Jacco van Rheenen; Xiaoyan Song; Wies van Roosmalen; Michael Cammer; Xiaoming Chen; Vera Desmarais; Shu-Chin Yip; Jonathan M Backer; Robert J Eddy; John S Condeelis
Journal:  J Cell Biol       Date:  2007-12-17       Impact factor: 10.539

View more
  11 in total

1.  Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry.

Authors:  Rebecca J Hermann; Travis Van der Steen; Emilie E Vomhof-Dekrey; Sejaa Al-Badrani; Steve B Wanjara; Jarrett J Failing; Jodie S Haring; Glenn P Dorsam
Journal:  J Immunol Methods       Date:  2011-11-04       Impact factor: 2.303

2.  Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells.

Authors:  Sheri Tinnell Dorsam; Emilie Vomhof-Dekrey; Rebecca J Hermann; Jodie S Haring; Travis Van der Steen; Erich Wilkerson; Goran Boskovic; James Denvir; Yulia Dementieva; Donald Primerano; Glenn Paul Dorsam
Journal:  Mol Immunol       Date:  2010-02-01       Impact factor: 4.407

Review 3.  Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents.

Authors:  Mario Delgado; Doina Ganea
Journal:  Brain Behav Immun       Date:  2008-06-14       Impact factor: 7.217

4.  Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.

Authors:  Emilie E Vomhof-DeKrey; Ashley R Sandy; Jarrett J Failing; Rebecca J Hermann; Scott A Hoselton; Jane M Schuh; Abby J Weldon; Kimberly J Payne; Glenn P Dorsam
Journal:  Peptides       Date:  2011-08-22       Impact factor: 3.750

5.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

6.  Vasoactive intestinal peptide receptor 1 is downregulated during expansion of antigen-specific CD8 T cells following primary and secondary Listeria monocytogenes infections.

Authors:  Emilie E Vomhof-DeKrey; Jodie S Haring; Glenn P Dorsam
Journal:  J Neuroimmunol       Date:  2011-03-10       Impact factor: 3.478

7.  Vasoactive intestinal peptide maintains the nonpathogenic profile of human th17-polarized cells.

Authors:  Rebeca Jimeno; Javier Leceta; Carmen Martínez; Irene Gutiérrez-Cañas; Mar Carrión; Selene Pérez-García; Marina Garín; Mario Mellado; Rosa P Gomariz; Yasmina Juarranz
Journal:  J Mol Neurosci       Date:  2014-05-08       Impact factor: 3.444

8.  A transcriptionally permissive epigenetic landscape at the vasoactive intestinal peptide receptor-1 promoter suggests a euchromatin nuclear position in murine CD4 T cells.

Authors:  K D Benton; R J Hermann; E E Vomhof-DeKrey; J S Haring; T Van der Steen; J Smith; S Dovat; G P Dorsam
Journal:  Regul Pept       Date:  2009-09-01

Review 9.  Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

Authors:  Yossan-Var Tan; James A Waschek
Journal:  ASN Neuro       Date:  2011-10-06       Impact factor: 4.146

10.  VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.

Authors:  Catalina Abad; Bhavaani Jayaram; Laurine Becquet; Yuqi Wang; M Sue O'Dorisio; James A Waschek; Yossan-Var Tan
Journal:  J Neuroinflammation       Date:  2016-06-29       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.